Lilly’s Foundayo: First Daily Pill Approved for Weight Loss, But How Does It Compare?
For the first time, the FDA has approved a small-molecule pill specifically targeting glucagon-like peptide-1 (GLP-1) for weight loss. The once-daily oral medication, Foundayo, developed by Eli Lilly and Company, offers a new option for individuals who may prefer a pill over the currently popular range of GLP-1 injections.
Foundayo contains the active ingredient orforglipron and will be shipped to patients with prescriptions starting April 6, according to the company. The approval comes as pharmaceutical companies race to develop more accessible weight-loss treatments.
Foundayo’s most direct competitor will be an oral version of Novo Nordisk’s Wegovy, which received FDA approval in December. Both pills utilize the same class of drugs – GLP-1s – that mimic a naturally occurring hormone regulating blood sugar, slowing digestion, and promoting feelings of fullness. However, Foundayo offers a key convenience factor: it can be taken at any time of day without food or water restrictions. In contrast, the Wegovy pill requires an empty stomach immediately upon waking, with a specific amount of water, and a 30-minute wait before consuming anything else.
“We think on-time approval and no food effect restrictions make orforglipron slightly more favorable vs oral [Wegovy] pill, which does have a food effect, but again net-net both are similar and can help expand and split the market,” UBS Bank analysts wrote on April 1.
Clinical trials showed that participants taking the highest dose of Foundayo lost an average of 12.0% of their body weight after 72 weeks, compared to just 0.9% for those on a placebo. Although effective, the weight loss achieved with the highest doses of both Lilly’s and Novo Nordisk’s pill forms is less than that seen with their respective injectable medications.
Lilly’s success with Foundayo marks a significant milestone in the development of small-molecule GLP-1 weight-loss pills. Experts note that these smaller molecules offer advantages over peptide-based drugs, including easier absorption by gut cells and potentially lower manufacturing costs.
The FDA’s expedited approval of Foundayo was granted under the controversial Commissioner’s National Priority Voucher pilot program, shortening the review time considerably. The agency stated this was the fastest approval for a new molecular entity since 2002.
Lilly anticipates the cost of Foundayo will be as low as $25 per month for those with commercial insurance, while self-pay patients could see prices starting at $149 per month.
This approval adds to a landmark year for Lilly, which became the first pharmaceutical company to reach a $1 trillion stock market value, largely driven by sales of its peptide weight-loss and antidiabetes injectables, Zepbound, and Mounjaro. The company had already stockpiled approximately $1.5 billion worth of the active ingredient for orforglipron by the end of 2025 in anticipation of approval.
Lilly is also pursuing other weight-loss therapies, including eloralintide, which mimics the hormone amylin, and retatrutide, a once-weekly injectable targeting three receptors simultaneously.
Context Box:
Understanding GLP-1s
GLP-1 (glucagon-like peptide-1) medications work by mimicking a natural hormone in the body that regulates blood sugar, slows digestion, and signals fullness to the brain. Originally developed for type 2 diabetes, these drugs have been found to be effective for weight loss, even in individuals without diabetes. Both injectable and oral forms are available, with injectables generally demonstrating greater weight loss in clinical trials.
As more options become available, will the convenience of a daily pill outweigh the greater weight loss potential of injectable GLP-1 medications for many patients?
